Trials / Recruiting
RecruitingNCT06693986
Adenovirus (RGDCRAdCOX2F)
A Phase I Study of a Tropism Modified Conditionally Replicative Adenovirus Vector (RGDCRAdCOX2F) for Endoscopic, Direct-Tumor Delivery in Pancreatic Adenocarcinoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Masonic Cancer Center, University of Minnesota · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single center, Phase I dose finding study of a single direct tumor injection of an RGD modified conditionally replicative adenovirus (RGDCRAdcox2F) in persons with adenocarcinoma of the pancreas. The study is designed to determine the MTD of RGDCRAdCOX2F that corresponds to the maximum desired toxicity of ≤ 20%.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Replicative Adenovirus Vector (RGDCRAdCOX2F) | RGDCRAdcox2F (RGD) is a "local" product and is provided through this study. |
Timeline
- Start date
- 2024-12-27
- Primary completion
- 2028-10-15
- Completion
- 2029-10-15
- First posted
- 2024-11-19
- Last updated
- 2026-01-07
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06693986. Inclusion in this directory is not an endorsement.